Glenmark launches triple drug formulation for type 2 diabetes patients in India
Source: Financial Express
Glenmark’s Zita portfolio of medicines has been benefiting around 1.75 million Type 2 diabetic patients annually, in India.
Glenmark Pharmaceuticals Limited on Wednesday announced that it has launched in India the first triple-drug fixed-dose combination (FDC) of the widely-used Teneligliptin with Dapagliflozin and Metformin.
According to press statement, this FDC has been launched under the brand name Zita DM, and it contains the DPP4 inhibitor, Teneligliptin (20mg), the SGLT2 inhibitor, Dapagliflozin, (10mg), and Metformin SR (500mg/1000mg) in a fixed dose. It must be taken once daily, under prescription, to improve glycemic control in patients with Type 2 diabetes.
“India has the second‐largest diabetic population in the world and Type 2 diabetic patients here often face issues of uncontrolled Hemoglobin A1C (HbA1Ci), beta cell dysfunction, which impairs insulin secretion, along with other co‐morbidities like weight gain. Diabetes management, hence, becomes difficult for these patients and a challenge for healthcare providers. Being a leader in treating diabetes, we are proud to introduce Zita DM,” Alok Malik, President & Business Head ‐ India Formulations, Glenmark Pharma stated on Wednesday.
Malik also said that this novel and affordable anti‐diabetic drug, helps improve glycemic control among adult patients with high HbA1c and other co‐morbidities; while also reducing major renal and cardiac adverse events. “With this robust profile, we are positive Zita DM will facilitate patient adherence to chronic diabetes treatments,” he added.
Glenmark’s Zita portfolio of medicines has been benefiting around 1.75 million Type 2 diabetic patients annually, in India. With the launch of Zita DM, Zita the most comprehensive gliptin range now holds promise of helping Type 2 diabetic patients at every stage of their treatment, the company stated.
According to IQVIATM sales data for the 12-month period ending August 2023 (MAT August 2023), the market for oral anti-diabetic drugs in India is estimated to be INR 12,522 crores, with an annual growth of 6.5 per cent against the corresponding period last year (MAT August 2022). As per the ICMR-INDIAB study conducted between 17th October 2008 and 17th December 2020, the overall weighted prevalence of diabetes was 11.4 per cent.
subramanyan
October 19, 2023txs for posting latest launches.